Navigation Links
John Theurer Cancer Center to host inaugural Mantle Cell Lymphoma Symposium
Date:11/7/2011

HACKENSACK, N.J. (November XX, 2011) The Lymphoma Division of the John Theurer Cancer Center at Hackensack University Medical Center with the participation from the Facebook groups "Hope for Lymphoma" and "Our MCL Family," will host its first-ever Mantle Cell Lymphoma Symposium on Saturday, November 12 from 8:30am 3:45pm. The event is open to both healthcare professionals and also to Mantle Cell Lymphoma (MCL) patients and their caregivers coping with this challenging diagnosis.

The complimentary Continuing Medical Education (CME) program will feature an international faculty of leading MCL experts who will review the latest advances in research, state-of-the-art- treatment options for new and relapsed disease and new and novel therapies for MCL.

MCL is a B-cell blood cancer called so because tumors are composed of cells that come from the "mantle" zone of the lymph node. It is one of the rarest and most challenging to treat of the non-Hodgkin's lymphomas (NHLs), comprising about 6% of NHL cases and currently affects about 15,000 patients in the U.S.

"MCL research has advanced the treatment options available and doubled the life expectancy for patients with this disease, but there is still much more work to be done," said Andre Goy, M.D., M.S., Chairman and Director and Chief of Lymphoma, John Theurer Cancer Center. "We can continue to develop better treatment options by collaborating with our patients. This will help them better understand and manage their disease to help move our clinical research forward."

A leading MCL researcher, member of the prestigious Mantle Cell Consortium and a member of the Lymphoma Research Foundation's esteemed Scientific Advisory Board, Dr. Goy was the Principal Investigator on the pivotal PINNACLE study, which led to the approval of the drug VELCADE, a treatment for relapsed MCL.

"Our group is honored to collaborate with Dr. Goy and the John Theurer Cancer Center to help provide patients, oncologists and other healthcare professionals with the kind of information usually only gleaned in big medical conferences," said Liz Hart McMillan, a five-year lymphoma survivor and co-founder of the "Our MCL Family" Facebook group which provides education and support to MCL survivors and caregivers.

The Mantle Cell Lymphoma Symposium will be streamed live from the MCL Facebook group and JTCancerCenter.org. Survivors, caregivers and healthcare professionals from around the world will have the opportunity to watch the event and ask questions in real time using the MCL Facebook group chat feature.

"We're excited to be the first Facebook group to use Livestreaming for patient education and to build awareness of clinical trials of novel therapies, which often offer the very best treatment options for this and other rare cancers," said Ms. McMillan.

Topics to be discussed at the Mantle Cell Lymphoma Symposium include the latest treatment options for new and relapsed MCL, novel and emerging therapies in managing MCL, the role of stem cell transplantation, the emerging role of maintenance therapies and optimizing MCL survivorship through scientifically backed nutrition, exercise and integrative therapies. The event includes complimentary breakfast and lunch.

The international panel of experts will update patients and healthcare professionals on the most recent advances in treatment and research. Speakers and their topics include:

  • Andre Goy, M.D., M.S. Chairman and Director, Chief of Lymphoma, the John Theurer Cancer Center: Working Toward Cure and Less Toxic Treatment: Emerging and Novel Therapies for MCL
  • Elias Campo, M.D, Ph.D. Chief, Hematopathology Unit and Clinical Director, Center for Biomedical Diagnosis, Hospital Clinic, University of Barcelona: Understanding the Biology and Prognostic Markers of MCL
  • Jorge E. Romaguera, M.D. Deputy Chairman, Division of Cancer Medicine, Lymphoma/Myeloma; and Professor, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center: Latest Frontline Treatments for MCL
  • Christian Geisler, M.D., PhD. Chairman of the Nordic Group Mantle Cell Lymphoma Subcommittee, Oncologist, Department of Hematology, Rigshospitalet (Chief Hospital of Denmark), Copenhagen: Impact of High Dose Frontline Therapy with Autologous Stem Cell Transplant on Outcome: the Nordic Group's Experience
  • Scott Rowley, M.D. Chief, Blood and Marrow Stem Cell and Transplantation Program, John Theurer Cancer Center: Options for Relapsed or Refractory MCL
  • Mr. David Miller, 9 year Mantle Cell Lymphoma Survivor, Aspen, CO: Perspectives from an Expert Patient and Long-Term Survivor

"The John Theurer Cancer Center is proud to be among the leading lymphoma programs in the world, " said Andrew L. Pecora, M.D., F.A.C.P., C.P.E., Chief Innovations Officer, Professor and Vice President of Cancer Services at John Theurer Cancer Center. "We are committed to empowering our patients with information and to promoting research through the education of physicians and patients."


'/>"/>

Contact: Amy Leahing
amy.leahing@zibbel.com
305-458-0599
John Theurer Cancer Center
Source:Eurekalert

Related medicine news :

1. John Theurer Cancer Center hosts New Frontiers in the Management of Solid and Liquid Tumors
2. John Theurer Cancer Center among first clinical trial sites to join landmark MMRF study
3. Lymphoma Research Foundation and John Theurer Cancer Center collaborate for Lymphoma Rounds program
4. John Theurer Cancer Center and the Promise Foundation partner to offer free skin cancer screenings
5. The John Theurer Cancer Center to host Seventh Annual Neuro-Oncology Symposium
6. John Theurer Cancer Center first in New Jersey to offer complete capabilities of Provenge
7. The MMRF and John Theurer Cancer Center to host patient symposium
8. John Theurer Cancer Center orthopedic oncologist shares new limb sparing surgical techniques
9. John Theurer Cancer Center to host Eighth Annual Northern New Jersey Breast Cancer Conference
10. Oncology basic research director at John Theurer Cancer Center continues transplantation research
11. John Theurer Cancer Center presents studies on promising therapies for aggressive blood cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
(Date:6/24/2016)... ... ... Marcy was in a crisis. Her son James, eight, was out of control. Prone to ... , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there ... my other children and say he was going to kill them. If we were ...
(Date:6/24/2016)... ... 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida ... their peers for this recognition are considered among the top 2 percent of lawyers ... as members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Comfort ... the American Cancer Society and the Road To Recovery® program to drive cancer patients ... seniors and other adults to ensure the highest quality of life and ongoing independence. ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
(Date:6/24/2016)... 2016  Consumers have taken a more active ... more emphasis on patient outcomes. ... the pharmaceutical industry have evolved beyond just providing ... are focusing on becoming more patient-oriented across their ... services that improve health. ...
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
Breaking Medicine Technology: